
US drug deaths plunged in 2024. Trump cuts may reverse that, experts warn.
Advertisement
The progress comes after drug deaths, which had been rising for more than a decade, soared to staggering levels during the coronavirus pandemic, surpassing 100,000 each year starting in 2021.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
'I would characterize this as a historically significant decrease in overdose deaths,' said Brandon Marshall, a Brown University School of Public Health epidemiologist who studies overdose trends. 'We're really seeing decreases almost across the entire nation at this point.'
The data published Wednesday charts a dramatic decline in deaths during then-President Joe Biden's final year in office. The Trump administration has espoused hard-line rhetoric on fentanyl, declaring traffickers a top national security threat and citing them as a key reason for launching trade battles with China and allies Canada and Mexico.
The administration has also touted large fentanyl seizures and asked Mexico to allow the US military to conduct counternarcotics operations on Mexican soil, a request denied by that country's president.
Advertisement
The CDC, in a statement, noted that Trump during his first administration declared the opioid crisis a public-health emergency in 2017. The declines since 2023 are a 'strong sign that public health interventions are making a difference and having a meaningful impact,' the agency said. 'Despite these overall improvements, overdose remains the leading cause of death for Americans aged 18-44, underscoring the need for ongoing efforts to maintain this progress.'
The White House Office of National Drug Control Policy, in an April statement of policy priorities, emphasized curbing the flow of illicit fentanyl, along with expanding access to treatment and research into cutting-edge technologies to identify and address emerging drug threats.
But public health advocates are raising alarm that the Trump administration is undercutting those goals with plans to gut federal funding that helps states pay for overdose antidotes, addiction treatment and other measures. A survey conducted by the nonprofit research firm Rand published in May suggests that more people may be using illicit opioids than previously estimated, underscoring the need for better monitoring.
In a letter to Congress on Monday, more than 300 academics warned that the Trump administration's proposed cuts to the Substance Abuse and Mental Health Services Administration and CDC could 'undermine the hard-fought progress we have made, especially in overdose prevention.'
Experts also worry Republican plans to slash Medicaid could leave former drug users without access to medication, forcing them to turn to street drugs, said Chad Sabora, a drug policy expert who helped organize the letter. 'It will equal more people dying,' he said.
Advertisement
What explains the drop?
The opioid crisis began decades ago with highly addictive prescription pain killers flooding states. Users later turned to cheaper street heroin, which was largely replaced by fentanyl manufactured by Mexican organized crime groups with precursor chemicals sourced from China. The synthetic drug can be up to 50 times more potent than heroin.
No single reason explains the sudden drop in deaths, researchers and health officials stress.
The Biden administration credited seizures of fentanyl at the southern border, arrests of high-level Mexican drug traffickers and cooperation from Beijing to crack down on unscrupulous Chinese companies exporting precursor chemicals. The administration also expanded access to addiction treatment medications such as buprenorphine, which wards off opioid withdrawals, and the overdose reversal drug naloxone. It also embraced harm reduction organizations that have saturated communities with free naloxone, fentanyl test strips and sterile needles to users.
Fewer deaths 'don't just happen overnight. And that's why we can credit them to the Biden administration's work,' said Sheila P. Vakharia, deputy director of research and academic engagement for the nonprofit Drug Policy Alliance.
Experts also believe that
the illicit drug supply, at least in some regions, may be shifting to include less fentanyl. Other drugs added to fentanyl - such as the tranquilizer xylazine - may prolong the sedating effect and
stave off opioid withdrawal so that users consume less fentanyl each day, researchers theorize.
Declines in deaths may also reflect the grim reality that fentanyl has killed so many regular users that there are fewer people at risk of overdose. The trajectory of deaths 'can't keep going up. It has essentially to kind of burn itself out,' said Caleb Banta-Green, an addiction expert and drug researcher at the University of Washington School of Medicine.
Advertisement
During Biden's first three years, the death toll topped 100,000 each year.
Deaths during a 12-month period peaked in June 2023 at a staggering 114,670, making the rapid drop nationally all the more remarkable, said Nabarun Dasgupta, an epidemiologist at the University of North Carolina at Chapel Hill. He stressed that deaths had been falling in certain regions where fentanyl had been entrenched for longer.
'Americans have responded to the overdose crisis with powerful community efforts, from every small town to large city. What we are seeing is the fruit of all that collective labor. These local efforts are the heart of overdose prevention,' Dasgupta said.
A state-by-state look
The CDC data released on Wednesday is not definitive; final death statistics lag because toxicology testing often takes months to complete.
Deaths involving stimulants such as methamphetamine and cocaine - which users increasingly take alongside fentanyl - also decreased, the statistics show.
Two states, Nevada and South Dakota notched slight increases from the previous year. But nearly all states showed declines in 2024. States such as New Hampshire, West Virginia and Ohio recorded declines of 35 percent or more.
In Washington state, where fentanyl became entrenched years later than on the East Coast, suspected drug deaths dropped by nearly 12 percent, after years of increases, for a total of 3,167.
In King County, home to Seattle, health officials distributed 124,700 naloxone kits in 2024 and opened three vending machines for people to obtain the medication, fentanyl test strips and other supplies.
County officials and the University of Washington Department of Emergency Medicine also debuted a hotline for doctors to prescribe buprenorphine through free telehealth sessions at any time of day. The city's mayor in August announced an investment of nearly $3 million in opioid litigation settlement money to increase capacity for inpatient treatment.
Advertisement
But the state health department's top medical officer, Tao Kwan-Gett, urged cautioned. Washington overdose deaths fell through much of 2024 but spiked during the final four months of the year.
'It's too early to say that we're seeing a sustained decrease,' Kwan-Gett said. 'I certainly hope we are, but I think we have to continue being vigilant.'
The encouraging statistics in Washington and nationwide belie the heartbreak of addiction - and death.
Among the victims nationwide in 2024: a 17-month-old Los Angeles boy who ingested fentanyl during a child welfare-monitored visit with his mother; a 15-year-old girl who fatally overdosed on fentanyl at her Georgia high school, nine people who fatally overdosed in Austin, during one day.
In Seattle, former movie set designer Wade Paradise battled an opioid addiction for years after taking prescription pain killers. He was largely estranged from his family, living in squalor and suffering from myriad ailments, according to his daughter, Nathalie Paradise, 24.
She said Wade Paradise had struggled to get addiction treatment because of problems with health insurance. In December, he died at age 68 in his home from a pill made of fentanyl. His death received little attention but for Nathalie's GoFundMe page in which she recalled cherished childhood memories of summer swims in a lake and bargain hunting at thrift stores - and detailed his addiction.
'I didn't want it to be a secret anymore. I felt like the people in his life deserved to know the truth,' she said in an interview. 'I also have a lot of friends who use drugs, and I hoped that by sharing my story, it might encourage them to stop.'
Advertisement
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Talkiatry Chief Medical Officer and co-founder Dr. Georgia Gaveras, DO named to Modern Healthcare's 50 Most Influential Clinical Executives Class of 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatry and therapy services, is proud to announce that co-founder and Chief Medical Officer Dr. Georgia Gaveras, DO has been recognized by Modern Healthcare as one of the 50 Most Influential Clinical Executives for 2025. Detailed profiles of all the honorees are featured in the June 9, 2025 issue of Modern Healthcare's magazine and online at This program honors licensed clinicians in executive roles who are recognized by the senior editors of Modern Healthcare and selected for their exceptional achievements in driving innovation, improving outcomes, serving their communities, and demonstrating exemplary leadership both within and beyond their organizations. "Becoming a clinician doesn't automatically prepare one for a leadership role, helping to guide an organization or an industry. The 50 clinicians chosen this year as the most influential, some newcomers and some we have recognized previously, are having an oversized impact," said Mary Ellen Podmolik, editor-in-chief of Modern Healthcare. "Their work is benefiting their own teams in terms of clinical advancements and financial results and is leading to better patient outcomes." With more than 600 licensed psychiatrists and 150+ therapists treating children, adults, and seniors for conditions including ADHD, anxiety, bipolar disorder, depression, OCD, and PTSD, Talkiatry has expanded to 47 states and reaches over 70% of commercially insured Americans through partnerships with more than 60 insurance providers, including Blue Cross Blue Shield, Aetna, United Healthcare, Cigna, and Humana. As access has increased, Talkiatry's dedication to high-quality care continues to lead to positive patient outcomes. In peer-reviewed clinical findings, two out of three patients saw their anxiety symptoms drop below clinically significant levels, and a similar portion experienced the same improvement with depression. Notably, one out of three patients achieved full remission in under 15-weeks. Among those who did not reach these thresholds, the vast majority still reported measurable improvement. Talkiatry is a physician-led practice where quality care comes first. Clinicians have the autonomy to make the best decisions for their patients, supported by structured clinical leadership, peer collaboration, and continuous education. To deliver these outcomes, Talkiatry has built an environment that prioritizes clinician support and sustainability. All clinicians receive structured onboarding, access to ongoing clinical education, and support from dedicated teams that handle scheduling, billing, and credentialing. Talkiatry is a community of like-minded, mission-driven peers. Through clinical chats, mentorship, grand rounds, and peer case consultations, the organization fosters connection, knowledge sharing, and a sense of belonging. "This recognition is a testament to the vital work the Talkiatry team is doing to expand access to high quality mental health care, regardless of a patient's geography or circumstance. Being named one of Modern Healthcare's 50 Most Influential Clinical Executives reinforces the importance of our mission, and I am incredibly grateful to be part of a movement that is transforming the way mental health care is delivered in this country." - Dr. Georgia Gaveras, Co-Founder & Chief Medical Officer, Talkiatry. For information or questions about the 50 Most Influential Clinical Executives program, please contact: MH Awards mhawards@ About Modern HealthcareModern Healthcare is the most trusted business news and information brand in the healthcare industry. Modern Healthcare empowers healthcare leaders and influencers to make timely and informed business decisions. To learn more or subscribe, go to About TalkiatryTalkiatry is a national mental health practice that provides in-network psychiatry and therapy. Co-founded by Robert Krayn and Georgia Gaveras, DO, Talkiatry is solving the core challenges patients and clinicians face in accessing and providing high-quality mental healthcare. With over 2 million patient visits delivered by a growing team of 600+ full-time psychiatrists and 150+ full-time therapists, Talkiatry is the largest dedicated psychiatry practice in the U.S. Our technology platform removes administrative burdens so clinicians can focus solely on patient care, resulting in strong clinical outcomes and significantly lower burnout. At Talkiatry, we're reimagining psychiatric care to be accessible, human, and responsible. Learn more at and follow us on LinkedIn, Facebook, and Instagram. Media Contactpress@ View original content to download multimedia: SOURCE Talkiatry Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
CareSource announces John Koehn as Massachusetts market president following its recent affiliation with Commonwealth Care Alliance
John Koehn DAYTON, Ohio and BOSTON, June 09, 2025 (GLOBE NEWSWIRE) -- CareSource, a nationally recognized nonprofit managed care organization, announced the appointment of John Koehn as the Massachusetts market president, effective today. This announcement follows CareSource's recent affiliation with Commonwealth Care Alliance (CCA), a nonprofit organization committed to providing innovative health plans and care delivery programs for individuals with significant health needs. Koehn brings extensive and proven health care experience in integrated Long-Term Services and Supports (LTSS) to his role at CCA. His prior experience includes serving as market president for AmeriHealth Caritas's LTSS program in Pennsylvania, where, under his leadership, the organization saw its first profitable year which enabled reinvestments in members and communities. Additionally, as health plan president at Amerigroup New Jersey, Koehn implemented strategies that helped the organization achieve the highest quality scores in the state. Most recently, he served as senior vice president of external affairs at InnovAge, where he led government relations efforts at both state and federal levels. "John's health care and leadership expertise are exactly what we need to ensure residents of Massachusetts with complex health needs continue to have access to person-centered, high-quality health care," said Erhardt Preitauer, CEO of CareSource. "His commitment to operational excellence and the member and caregiver experience will help to ensure CCA's long-term sustainability and strong commitment to our members, patients and the Commonwealth.' CareSource, through its affiliation with CCA, serves nearly 50,000 Massachusetts residents, many of whom face significant health challenges and social barriers. The organization also provides specialized primary care and innovative clinical programs, including a respite care unit for individuals experiencing acute behavioral health crises. In his new role, Koehn will work closely with CareSource leadership and the executive team of CCA to ensure a seamless integration of services and operations to bolster the services and supports available to individuals with complex health needs in Massachusetts. "Joining CareSource at this pivotal time is an honor," said Koehn. "I look forward to working alongside our talented CCA team to strengthen partnerships and ensure that everyone in Massachusetts has access to coordinated care that can genuinely enhance their quality of life.' Koehn holds a Master of Arts degree in History from the University of Michigan and a Bachelor of Arts degree in History from the University of Connecticut. He will be based in Massachusetts as he steps into his new role. About CareSourceCareSource is a nonprofit, nationally recognized managed care organization with over two million members. CareSource administers one of the largest Medicaid managed care plans in the U.S. The organization offers health insurance, including Medicaid, Health Insurance Marketplace and Medicare products. As a mission-driven organization, CareSource is transforming health care with innovative programs that address the social determinants of health, prevention and access to care. For more information, visit us at or follow us on X, formerly known as Twitter, LinkedIn or Facebook. About Commonwealth Care Alliance Commonwealth Care Alliance® (CCA) is a mission-driven healthcare services organization that offers innovative health plans and care delivery programs designed for individuals with the most significant needs. Through our flagship Senior Care Options (SCO) and One Care plans in Massachusetts, CCA delivers comprehensive, integrated, and person-centered care by coordinating the services of local staff, provider partners, and community-based organizations to meet the unique needs of each individual we serve. Attachment John Koehn CONTACT: Vicki McDonald CareSource 216.502.6395 Sarah Magazine Commonwealth Care Alliance 617.470.6755 mediainquiries@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Politico
37 minutes ago
- Politico
Efforts to bolster organ donation in New York
Beat Memo Thousands of New York residents are waiting for a kidney transplant, and a long-delayed state program could soon spur more donors. The state Department of Health recently laid the groundwork for a new initiative to reimburse living organ donors for expenses not covered by insurance — over two years after lawmakers passed legislation to establish a living donor support program. Up to $14,000 in financial assistance would be available for lost wages, travel, food, lodging, child care, elder care and health care costs related to the donor's organ removal surgery. 'By further removing financial barriers, more New Yorkers will be empowered to become a living donor and give the enormous and selfless gift of life,' Cadence Acquaviva, a spokesperson for the Department of Health, said in a statement. Because living donors can only give a kidney — or parts of their lung, liver and pancreas — the program is expected to be particularly helpful to kidney failure patients, who comprise roughly 7,000 of the 8,000 New Yorkers waiting for an organ transplant. New Yorkers awaiting an organ transplant could also benefit from a bill known as the HEART Act, which passed both chambers last week. If signed, the Helping Equal Access to Registrations for Transplants Act would repeal a 35-year-old ban that prevents New Yorkers who need a transplant from enlisting with multiple transplant centers. The goal is to increase the likelihood that people receive a transplant and to reduce their wait time by a matter of years. The measure received bipartisan support in both the Assembly and Senate. 'Through the HEART Act, we're creating a more equitable system and saving the lives of hundreds of New Yorkers,' bill sponsor Sen. April Baskin said in a statement. 'This is just one more step in our continuous work alongside legislative leaders and Donate Life New York State to strengthen the organ donation system and create a giving culture across the state.' IN OTHER NEWS: — NYC Health + Hospitals will expand its hospital-based violence interruption programming to Bellevue and Elmhurst Hospitals in the coming year, as the system continues work to unify its approach to treating victims of violent trauma and addressing gun violence as a public health crisis. 'Violence is more than a criminal justice issue — it is a public health crisis with a prescription that demands a coordinated, holistic public health response,' NYC Health + Hospitals President and CEO Mitchell Katz said in a statement Friday. 'By unifying our Hospital-Based Violence Interruption Programs, we are advancing a systemwide model of trauma-informed care that meets victims at their most vulnerable moments and supports them through long-term healing.' — Two lawmakers are calling on the state Department of Health to allow Medicaid to cover anti-obesity medication, Assemblymembers Karines Reyes and Jeremy Cooney wrote in a letter Thursday. In their letter to state Health Commissioner James McDonald, Reyes and Cooney said the lack of access to GP-1 medications among low-income communities creates a systemic bias. 'Medicaid recipients represent some of the most vulnerable individuals in our healthcare system, and they deserve the same opportunity to benefit from life-saving treatments that are already transforming health outcomes across the state,' Reyes and Cooney wrote. ON THE AGENDA: — Monday at 1 p.m. The City Council hosts an oversight hearing on the state of older New Yorkers' mental health. — Wednesday at 10:15 a.m. The Early Intervention Coordinating Council will convene. — Friday at 10:30 a.m. The state Health Equity Council will meet. MAKING ROUNDS: — Chip Kahn, president and CEO of the Federation of American Hospitals, announced plans to retire at the end of the year after 24 years leading the trade association. GOT TIPS? Send story ideas and feedback to Maya Kaufman at mkaufman@ and Katelyn Cordero at kcordero@ Want to receive this newsletter every weekday? Subscribe to POLITICO Pro. You'll also receive daily policy news and other intelligence you need to act on the day's biggest stories. What you may have missed — The 'aid-in-dying' bill is set to pass the Senate in the final days of the legislative session, Sen. Majority Leader Andrea Stewart-Cousins confirmed to reporters Thursday. The decade-old proposal would allow doctors to prescribe euthanizing medication to patients with terminal illnesses. It passed the Assembly by a narrow margin in April. Stewart-Cousins confirmed Thursday that a majority of members in her conference said they will vote in favor of the measure, POLITICO Pro's Katelyn Cordero reports. ODDS AND ENDS NOW WE KNOW — Most Americans are worried about the impact of Congress' proposed Medicaid cuts, a new poll shows. TODAY'S TIP — With whooping cough on the rise, here's what you need to know about staying protected. STUDY THIS — A new study by researchers at the University of California finds a link between iron deficiency and Crohn's disease. WHAT WE'RE READING — CDPAP check-in: where the state's controversial home care consolidation stands. (Crain's New York Business) — In axing mRNA contract, Trump delivers another blow to U.S. biosecurity, former officials say. (KFF Health News) Around POLITICO — Trump's NIH budget plan would make competing for grants much harder, Erin Schumaker reports. — Via POLITICO's Carmen Paun: Trump doesn't want the WHO's advice. It's giving some anyway. — The stealth Senate dealmaker who could deliver Trump tax cuts, Benjamin Guggenheim reports. MISSED A ROUNDUP? Get caught up on the New York Health Care Newsletter.